Gordon Noa, Dooley Cara, Murphy Áine, Farooq Wasfa, Sullivan Frank, McDermott Ray, Sharp Linda, Watson William, Galvin David
UCD School of Medicine and UCD Conway Institute, University College Dublin, Dublin, Ireland
UCD School of Medicine and UCD Conway Institute, University College Dublin, Dublin, Ireland.
BMJ Open. 2024 Dec 2;14(12):e090207. doi: 10.1136/bmjopen-2024-090207.
To describe the Irish Prostate Cancer Outcomes Research (IPCOR) registry. The cohort was collected to inform and improve the prostate cancer journey of men in Ireland.
Established in 2015, IPCOR was a unique large-scale prospective cohort study registering men with prostate cancer in Ireland. From 2016 to 2020, IPCOR collected data on 6816 men who were newly diagnosed with prostate cancer across 16 hospitals, both public and private. A comprehensive clinical dataset was collected, capturing detailed information on men's diagnosis, treatments and follow-up. In addition, a subset of 873 men completed patient-reported outcome measures.
The IPCOR study has revealed several key insights into prostate cancer diagnosis and treatment in Ireland. The data indicate a high rate of diagnosis through opportunistic Prostate-Specific Antigen screening, with many cases identified at an early stage.
IPCOR invites collaboration from the global cancer research community to use this resource to advance prostate cancer research and improve patient outcomes worldwide. IPCOR aims to continue updating long-term survival follow-up data for this cohort. It also plans to continue its collaborative approach with patients, engaging with the Lived Experience Advisory Panel in interpreting results emerging from this dataset. Moving forward, IPCOR is planning its next phase of the project, IPCOR 2.0. This will be a prospective, longitudinal, multi-centre clinical quality registry and biorepository.
描述爱尔兰前列腺癌结果研究（IPCOR）登记处。该队列旨在为爱尔兰男性前列腺癌的治疗历程提供信息并加以改善。
IPCOR于2015年设立，是一项独特的大规模前瞻性队列研究，登记了爱尔兰患有前列腺癌的男性。2016年至2020年期间，IPCOR收集了16家公立和私立医院6816名新诊断为前列腺癌男性的数据。收集了一个全面的临床数据集，获取了有关男性诊断、治疗和随访的详细信息。此外，873名男性的子集完成了患者报告的结局指标。
IPCOR研究揭示了爱尔兰前列腺癌诊断和治疗的几个关键见解。数据表明通过机会性前列腺特异性抗原筛查的诊断率很高，许多病例在早期就被发现。
IPCOR邀请全球癌症研究界合作，利用这一资源推进前列腺癌研究并改善全球患者的治疗结果。IPCOR旨在继续更新该队列的长期生存随访数据。它还计划继续与患者采用合作方式，与生活经验咨询小组合作解读该数据集中出现的结果。展望未来，IPCOR正在规划该项目下一阶段，即IPCOR 2.0。这将是一个前瞻性、纵向、多中心的临床质量登记处和生物样本库。
